RAPT Therapeutics (RAPT) Retained Earnings (2020 - 2024)
Historic Retained Earnings for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to -$561.3 million.
- Therapeutics' Retained Earnings fell 2368.68% to -$561.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$561.3 million, marking a year-over-year decrease of 2368.68%. This contributed to the annual value of -$484.7 million for FY2023, which is 3174.86% down from last year.
- Therapeutics' Retained Earnings amounted to -$561.3 million in Q3 2024, which was down 2368.68% from -$542.9 million recorded in Q2 2024.
- In the past 5 years, Therapeutics' Retained Earnings ranged from a high of -$175.1 million in Q1 2020 and a low of -$561.3 million during Q3 2024
- In the last 5 years, Therapeutics' Retained Earnings had a median value of -$323.7 million in 2022 and averaged -$343.5 million.
- As far as peak fluctuations go, Therapeutics' Retained Earnings tumbled by 3221.16% in 2021, and later crashed by 2368.68% in 2024.
- Therapeutics' Retained Earnings (Quarter) stood at -$214.8 million in 2020, then plummeted by 32.21% to -$284.0 million in 2021, then fell by 29.52% to -$367.9 million in 2022, then plummeted by 31.75% to -$484.7 million in 2023, then fell by 15.81% to -$561.3 million in 2024.
- Its Retained Earnings was -$561.3 million in Q3 2024, compared to -$542.9 million in Q2 2024 and -$515.2 million in Q1 2024.